Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
2026-10-16 17:54
•The Motley Fool Team •The Motley Fool
••• •• Axe Cap view
Johnson & Johnson’s Growth Signals Potential for Long-Term Stability
JNJ’s strong pharma performance and strategic moves offer lessons for patient investors.
Johnson & Johnson’s latest results show how steady growth in pharmaceuticals, especially cancer drugs, can anchor a company’s future. Their 6% rise in operational revenue and the prospect of surpassing $100 billion in sales is impressive—proof that big, diversified healthcare firms can still deliver. The struggles in its medical devices division, particularly from geopolitical issues and China's unique purchasing approach, remind us nothing is smooth. The planned spin-off of their orthopedics arm by mid-2027 could unlock value, but it’s a double-edged sword—sometimes splitting businesses can limit cross-division synergies. Local investors should watch USD/ZAR closely against JNJ’s dollar earnings; a weaker rand could boost rand returns but raise input costs for related companies like Aspen or Adcock Ingram exposed to imported pharma inputs. The main risk? Regulatory hurdles or competition in cancer drugs could hurt growth. this is just our opinion and not financial advice
Watch JNJ for a steady portfolio anchor if exposure to multinational pharma is needed, but hedge rand exposure due to currency swings. Avoid chasing the spin-off story until there is clearer detail.
- JNJ
- USD/ZAR
- Regulatory changes hitting drug approvals
- Rand volatility impacting import costs
6/10
Johnson & Johnson raised its full-year sales outlook after Q3 2026 operational revenue grew 6%, putting the company on track to exceed $100 billion in annual revenue for the first time. Strong pharmaceutical demand, particularly in cancer treatments, drove performance. However, the medical device segment faced headwinds with only 2.5% growth due to Middle East disruptions and China's bulk-buying program. Management plans to restore momentum through new product launches and is leaning toward spinning off its DePuy Synthes orthopedics subsidiary by mid-2027.
Our take is based on reporting first published by The Motley Fool.